Skip to main content

Advertisement

SpringerLink
Log in

Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objective

To determine the clinical and serologic similarities and differences between inflammatory arthritis induced by immune checkpoint inhibitors (IA-irAE) and rheumatoid arthritis (RA).

Methods

In this retrospective cross-sectional comparative study, 20 patients with IA-irAE were age and sex matched to 40 seropositive and 40 seronegative RA patients. Electronic medical records were reviewed from diagnosis of inflammatory arthritis through May 2019. Arthritis characteristics, treatment, and relevant laboratory and serologic studies were captured.

Results

Clinically, IA-irAE differed from seropositive and seronegative RA with respect to disease duration (4.18 versus 11.59 and 13.3 months, respectively, p = 0.005 (IA-irAE vs seropositive RA), p = 0.002 (IA-irAE vs seronegative RA)), polyarticular joint involvement at presentation (75% versus 97.5% and 100%, p = 0.013, p = 0.003), absence of erosive changes (5.9% vs 43.6% and 53.8%, p = 0.005, p = 0.001), mean prednisone dose (24.7 mg versus 16.53 mg and 15.68 mg, p = 0.008, p = 0.005), and use of methotrexate (5.0% versus 85.0% and 70.0%, p < 0.0001, p < 0.0001). Serologically, IA-irAE closely resembled seronegative RA. ANA positivity was seen in a minority of patients and did not differ significantly between all groups; however, the ANA staining pattern (speckled) was similar between IA-irAE and seronegative RA (100% versus 75%, respectively) and was not commonly observed in seropositive RA (18.2%).

Conclusion

IA-irAE is a new subset of IA that resembles seronegative RA immunologically. Our findings suggest that further study of IA-irAE might provide a window into underlying pathogenic mechanisms of early-stage seronegative RA.

Key Points

• Comprehensive comparison of clinical features between inflammatory arthritis irAE (IA-irAE) and regular rheumatoid arthritis indicates IA-irAE as a new subset of inflammatory arthritis.

• IA-irAE resembles seronegative RA immunologically, suggesting that study of IA-irAE may provide a window into underlying pathogenic mechanisms of early-stage seronegative RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148. https://doi.org/10.1016/j.ejca.2015.11.016

    Article  CAS  PubMed  Google Scholar 

  2. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168. https://doi.org/10.1056/NEJMra1703481

    Article  CAS  PubMed  Google Scholar 

  3. Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC (2020) Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 79(3):332–338. https://doi.org/10.1136/annrheumdis-2019-216109

    Article  CAS  PubMed  Google Scholar 

  4. Sebastiani GD, Scirocco C, Galeazzi M (2019) Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev 18(8):805–813. https://doi.org/10.1016/j.autrev.2019.06.005

    Article  CAS  PubMed  Google Scholar 

  5. Calabrese LH, Calabrese C, Cappelli LC (2018) Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 14(10):569–579. https://doi.org/10.1038/s41584-018-0074-9

    Article  PubMed  Google Scholar 

  6. Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U (2019) Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol 71(3):468–475. https://doi.org/10.1002/art.40745

    Article  CAS  PubMed  Google Scholar 

  7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580–1588. https://doi.org/10.1136/ard.2010.138461

    Article  PubMed  Google Scholar 

  8. Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T, Fhu A (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 77(3):393–398. https://doi.org/10.1136/annrheumdis-2017-212257

    Article  CAS  PubMed  Google Scholar 

  9. Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham CO 3rd (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76(1):43–50. https://doi.org/10.1136/annrheumdis-2016-209595

    Article  CAS  PubMed  Google Scholar 

  10. Gianchecchi E, Delfino DV, Fierabracci A (2013) Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev 12(11):1091–1100. https://doi.org/10.1016/j.autrev.2013.05.003

    Article  CAS  PubMed  Google Scholar 

  11. Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48(3):553–557. https://doi.org/10.1016/j.semarthrit.2018.02.011

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chang MH, Nigrovic PA (2019) Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight 4(5). https://doi.org/10.1172/jci.insight.125278

  13. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6:15. https://doi.org/10.1038/s41413-018-0016-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Supported by Mayo Foundation for Medical Education and Research.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Yuan Liu, Jane M. Jaquith, Kathleen Mccarthy-Fruin, Xingxing Zhu, Xian Zhou, Yanfeng Li, Cynthia Crowson, John M. Davis III, Uma Thanarajasingam & Hu Zeng

  2. Department of Rheumatology, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China

    Yuan Liu

  3. Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

    Cynthia Crowson

  4. Department of Immunology, Mayo Clinic, Rochester, MN, USA

    Hu Zeng

Authors
  1. Yuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane M. Jaquith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathleen Mccarthy-Fruin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xingxing Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xian Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yanfeng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cynthia Crowson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John M. Davis III
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Uma Thanarajasingam
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hu Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Uma Thanarajasingam or Hu Zeng.

Ethics declarations

Disclosure

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Jaquith, J.M., Mccarthy-Fruin, K. et al. Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis. Clin Rheumatol 39, 3631–3637 (2020). https://doi.org/10.1007/s10067-020-05162-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05162-9

Keywords

Search

Navigation